DDR1 and Alzheimer disease: Nilotinib penetrates the CNS (> 1 nM) and directly inhibits DDR1 and alters AD biomarkers, including Aβ as measured by PET, CSF Aβ42 and Aβ40, and the plasma ratio of Aβ42 to p-Tau217.